Machine learning for comprehensive forecasting of Alzheimer's Disease progression
September 20, 2019
We have shown that generative models capable of sampling conditional probability distributions over a diverse array of clinical variables can accurately model the...
Recruit Rockstars Podcast #367: How His VC-Backed Team Made Drug Development Faster
November 15, 2020
Unlearn helps biopharma companies develop drugs more efficiently by leveraging AI to reduce the number of patients required for placebo controls in clinical trials.
The Rock Health team reflects on the evolution of digital in clinical trials, discuss the current state, and explore the opportunity to further transform drug discovery.
Generating Digital Twins with Multiple Sclerosis Using Probabilistic Neural Networks
February 5, 2020
Using a dataset of subjects enrolled in the placebo arms of MS clinical trials, we trained a Conditional Restricted Boltzmann Machine to generate digital subjects.
Broadening Role for External Control Arms in Clinical Trials
July 12, 2019
Unlearn.AI Inc. is going a step further, using data from historical trials and patient registries to build algorithms that simulate artificial patients.
The ability to reduce the burden on control subjects with subjects in clinical trials for complex diseases like Alzheimer’s Disease would drastically improve the search..
